Your PDF has successfully downloaded.

You may be interested in finding more content on these topics:


You are not currently logged in.

Access JSTOR through your library or other institution:


Log in through your institution.

Journal Article

CCN1 suppresses pulmonary vascular smooth muscle contraction in response to hypoxia

Seon-jin Lee, Meng Zhang, Kebin Hu, Ling Lin, Duo Zhang and Yang Jin
Pulmonary Circulation
Vol. 5, No. 4 (December 2015), pp. 716-722
DOI: 10.1086/683812
Stable URL:
Page Count: 7
Were these topics helpful?
See somethings inaccurate? Let us know!

Select the topics that are inaccurate.

  • Download PDF
  • Add to My Lists
  • Cite this Item
We're having trouble loading this content. Download PDF instead.


AbstractPulmonary vasoconstriction and increased vascular resistance are common features in pulmonary hypertension (PH). One of the contributing factors in the development of pulmonary vasoconstriction is increased pulmonary artery smooth muscle cell (PASMC) contraction. Here we report that CCN1, an extracellular matrix molecule, suppressed PASMC contraction in response to hypoxia. CCN1 (Cyr61), discovered in past decade, belongs to the Cyr61-CTGF-Nov (CCN) family. It carries a variety of cellular functions, including angiogenesis and cell adhesion, death, and proliferation. Hypoxia robustly upregulated the expression of CCN1 in the pulmonary vessels and lung parenchyma. Given that CCN1 is a secreted protein and functions in a paracine manner, we examined the potential effects of CCN1 on the adjacent smooth muscle cells. Interestingly, bioactive recombinant CCN1 significantly suppressed hypoxia-induced contraction in human PASMCs in vitro. Consistently, in the in vivo functional studies, administration of bioactive CCN1 protein significantly decreased right ventricular pressure in three different PH animal models. Mechanistically, protein kinase A–pathway inhibitors abolished the effects of CCN1 in suppressing PASMC contraction. Furthermore, CCN1-inhibited smooth muscle contraction was independent of the known vasodilators, such as nitric oxide. Taken together, our studies indicated a novel cellular function of CCN1, potentially regulating the pathogenesis of PH.

Notes and References

This item contains 32 references.

  • 1.
    ['1. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E, Fishman AP. Primary pulmonary hypertension: vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989;80(5):1207–1221.']
  • 2.
    ['2. Tsai BM, Wang M, Turrentine MW, Mahomed Y, Brown JW, Meldrum DR. Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies. Ann Thorac Surg 2004;78(1):360–368.']
  • 3.
    ['3. Lowson S. Inhaled alternatives to nitric oxide. Anesthesiology 2002;96(6):1504–1513.']
  • 4.
    ['4. Blaise G, Langleben D, Hubert B. Pulmonary arterial hypertension: pathophysiology and anesthetic approach. Anesthesiology 2003;99(6):1415–1432.']
  • 5.
    ['5. Abe K, Toba M, Alzoubi A, Ito M, Fagan KA, Cool CD, Voelkel NF, McMurtry IF, Oka M. Formation of plexiform lesions in experimental severe pulmonary arterial hypertension. Circulation 2010;121(25):2747–2754.']
  • 6.
    ['6. Stenmark KR, Meyrick B, Galiè N, Mooi WJ, McMurtry IF. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297(6):L1013–L1032.']
  • 7.
    ['7. Ciuclan L, Bonneau O, Hussey M, Duggan N, Holmes AM, Good R, Stringer R, et al. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184(10):1171–1182.']
  • 8.
    ['8. Pappert D, Busch T, Gerlach H, Lewandowski K, Radermacher P, Rossaint R. Aerosolized prostacyclin versus inhaled nitric oxide in children with severe acute respiratory distress syndrome. Anesthesiology 1995;82(6):1507–1511.']
  • 9.
    ['9. Langer F, Wilhelm W, Tscholl D, Schramm R, Lausberg H, Wendler O, Schäfers H-J. Intraoperative inhalation of the long-acting prostacyclin analog iloprost for pulmonary hypertension. J Thorac Cardiovasc Surg 2003;126(3):874–875.']
  • 10.
    ['10. Vincent JL, Carlier E, Pinsky MR, Goldstein J, Naeije R, Lejeune P, Brimioulle S, Leclerc JL, Kahn RJ, Primo G. Prostaglandin E1 infusion for right ventricular failure after cardiac transplantation. J Thorac Cardiovasc Surg 1992;103(1):33–39.']
  • 11.
    ['11. Babic AM, Kireeva ML, Kolesnikova TV, Lau LF. CYR61, a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth. Proc Natl Acad Sci USA 1998;95(11):6355–6360.']
  • 12.
    ['12. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004;363(9402):62–64.']
  • 13.
    ['13. O’Brien TP, Yang GP, Sanders L, Lau LF. Expression of cyr61, a growth factor-inducible immediate-early gene. Mol Cell Biol 1990;10(7):3569–3577.']
  • 14.
    ['14. Grzeszkiewicz TM, Lindner V, Chen N, Lam SC, Lau LF. The angiogenic factor cysteine-rich 61 (CYR61, CCN1) supports vascular smooth muscle cell adhesion and stimulates chemotaxis through integrin α6ß1 and cell surface heparan sulfate proteoglycans. Endocrinology 2002;143(4):1441–1450.']
  • 15.
    ['15. Lau LF. CCN1/Cyr61: the very model of a modern matricellular protein. Cell Mol Life Sci 2011;68(19):3149–3163.']
  • 16.
    ['16. Jin Y, Kim HP, Cao J, Zhang M, Ifedigbo E, Choi AMK. Caveolin-1 regulates the secretion and cytoprotection of Cyr61 in hyperoxic cell death. FASEB J 2009;23(2):341–350.']
  • 17.
    ['17. Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, Reid LM, Tuder RM. Pathologic assessment of vasculopathies in pulmonary hypertension. J Am Coll Cardiol 2004;43(1):25–32.']
  • 18.
    ['18. Humbert M. Update in pulmonary hypertension 2008. Am J Respir Crit Care Med 2009;179(8):650–656.']
  • 19.
    ['19. Mooi WJ, Grünberg K. Histopathology of pulmonary hypertensive diseases. Curr Diagn Pathol 2006;12(6):429–440.']
  • 20.
    ['20. Morrell NW, Adnot S, Archer SL, Dupuis J, Jones PL, MacLean MR, McMurtry IF, et al. Cellular and molecular basis of pulmonary arterial hypertension J Am Coll Cardiol 2009;54(1 suppl.):S20–S31.']
  • 21.
    ['21. Meyrick BO, Perkett EA. The sequence of cellular and hemodynamic changes of chronic pulmonary hypertension induced by hypoxia and other stimuli. Am Rev Respir Dis 1989;140(5):1486–1489.']
  • 22.
    ['22. Dahm LM, Bowers CW. Vitronectin regulates smooth muscle contractility via αv and β1 integrin. J Cell Sci 1998;111(9):1175–1183.']
  • 23.
    ['23. Morgado M, Cairrão E, Santos-Silva AJ, Verde I. Cyclic nucleotide-dependent relaxation pathways in vascular smooth muscle. Cell Mol Life Sci 2012;69(2):247–266.']
  • 24.
    ['24. Pfitzer G. Regulation of myosin phosphorylation in smooth muscle. J Appl Physiol 2001;91(1):497–503.']
  • 25.
    ['25. Hartshorne DJ, Ito M, Erdödi F. Myosin light chain phosphatase: subunit composition, interactions and regulation. J Muscle Res Cell Motil 1998;19(4):325–341.']
  • 26.
    ['26. Kamm KE, Stull JT. Dedicated myosin light chain kinase with diverse cellular functions. J Biol Chem 2001;276(7):4527–4530.']
  • 27.
    ['27. Azam MA, Yoshioka K, Ohkura S, Takuwa N, Sugimoto N, Sato K, Takuwa Y. Ca2+-independent, inhibitory effects of cyclic adenosine 5′-monophosphate on Ca2+ regulation of phosphoinositide 3-kinase C2α, Rho, and myosin phosphatase in vascular smooth muscle. J Pharmacol Exp Ther 2007;320(2):907–916.']
  • 28.
    ['28. Murthy KS, Zhou H, Grider JR, Makhlouf GM. Inhibition of sustained smooth muscle contraction by PKA and PKG preferentially mediated by phosphorylation of RhoA. Am J Physiol Gastrointest Liver Physiol 2003;284(6):G1006–G1016.']
  • 29.
    ['29. Body SC, Hartigan PM, Shernan SK, Formanek V, Hurford WE. Nitric oxide: delivery, measurement, and clinical applications. J Cardiothorac Vasc Anesth 1995;9(6):748–763.']
  • 30.
    ['30. Zwissler B, Welte M, Messmer K. Effects of inhaled prostacyclin as compared with inhaled nitric oxide on right ventricular performance in hypoxic pulmonary vasoconstriction. J Cardiothorac Vasc Anesth 1995;9(3):283–289.']
  • 31.
    ['31. Hirschfeld M, zur Hausen A, Bettendorf H, Jäger M, Stickeler E. Alternative splicing of Cyr61 is regulated by hypoxia and significantly changed in breast cancer. Cancer Res 2009;69(5):2082–2090. doi:10.1158/0008-5472.CAN-08-1997.']
  • 32.
    ['32. Grzeszkiewicz TM, Kirschling DJ, Chen N, Lau LF. CYR61 stimulates human skin fibroblast migration through integrin αvβ5 and enhances mitogenesis through integrin αvβ3, independent of its carboxyl-terminal domain. J Biol Chem 2001;276(24):21943–21950.']